Dr Joe de Sousa is Senior Leader, Non-Executive Director and Consultant at Melhor Consulting.
Joe has over 25 years’ experience in line, project and scientific leadership positions across Pharmaceutical R&D.
Prior to his role as an independent consultant and founder of Melhor, Joe was Director of Science & Technology, Global Product Development at AstraZeneca where he set the culture and shaped the research activities of scientists across UK, US, Sweden and China focused on design and delivery of AstraZeneca’s current and future medicines and managed an extensive portfolio of science and technology projects that ensured AstraZeneca’s R&D capability maintained its world class status for innovation and excellence. Previous roles range across all phases of pharmaceutical R&D from pre-clinical all the way through clinical development, regulatory approval and new product launch.
Joe’s current portfolio extends across the Public Sector, Private Sector, Leading Universities and the Charity Sector. Some current responsibilities include Council Member at the Engineering & Physical Sciences Research Council (EPSRC) (ukri.org/councils/epsrc), Trustee at the British Science Association (britishscienceassociation.org) and Mentor at the Royal Society of Chemistry (rsc.org).
Joe completed a DPhil at University of Oxford in synthetic organic chemistry under the supervision of Professor Steve Davies after obtaining a Bachelors degree in Chemistry at University of York. He grew up in Manchester somewhat confused by the often disparate culture of his heritage (mother from Bournemouth and father from Lisbon) and the gritty northern surroundings of his childhood. This somewhat unusual mix along with his time in Yorkshire, Oxford and a brief interlude in Essex enable him to feel both an outsider and at home in so many different places.
About Joe de Sousa on the University of Cambridge R&D Management Conference site.
Related posts
A highlight of the year is the R&D Management Conference. The 2016 conference ‘From Science to Society: Innovation and Value Creation’ was held in Cambridge, UK, and the 2017 conference will be held at the University of Leuven, Belgium, from 2-5 July.
R&D Today officially launched at R&D Management Conference 2016; community website aims to be ‘trip advisor’ of best practice.
R&D Management Conference includes many sessions of interest to practitioners including keynotes by Warren East of Rolls-Royce plc, Joe de Sousa AstraZeneca, David Teece Haas School of Business and Mark Samuels NIHR.
Our scientists are all doing great work in diverse areas, how could I define this work to ensure it was creating value for the company? Stokes model of the Pasteur’s Quadrant provided the inspiration I needed, says Dr Joe de Sousa, Director Science & Technology, AstraZeneca
Pharmaceutical R&D is a complex, long and expensive task with a high project attrition rate. Only 5% of drug projects, that reach the stage of first human dose progress through all phases of clinical trials to reach patients.
A good understanding of the R&D pipeline and portfolio is essential to reduce waste, duplication and poor use of valuable resources, says Joe de Sousa of AstraZeneca
Large R&D centric businesses have a huge asset in the vast experience that exists in their leading scientists – every trick in the book should be used to help staff access this expertise…